887 results about "Melatonin" patented technology

One aspect of the present invention relates to pharmaceutical compositions comprising a sedative agent; and melatonin or a melatonin analog, collectively referred to as “melatonin agents.” In a preferred embodiment, the sedative agent is eszopiclone. The pharmaceutical compositions of the invention are useful in the treatment of various sleep disorders. In addition, the present invention also relates to a method of treating a patient suffering from a sleep abnormality or insomnia comprising administering a therapeutically effective amount of a pharmaceutical composition of the invention.

The present invention relates to a method and transdermal pharmaceutical composition for preventing or reducing the likelihood of calcium deficiency or imbalances caused by calcium deficiency. The transdermal pharmaceutical composition includes a therapeutically effective amount of a pharmaceutically acceptable salt of calcium and a pharmaceutically acceptable carrier constituting a pluronic lecithin organogel. In addition to calcium, the transdermal pharmaceutical composition may also contain a therapeutically effective amount of: (1) a pharmaceutically acceptably salt of other minerals such as magnesium, zinc, selenium, manganese, or chromium; (2) a vitamin such as vitamin A, vitamin D, vitamin C, vitamin E or B-complex vitamins, choline, lecithin, inositol, PABA, biotin, or bioflavomoids; (3) a carotenoid such as lycopene or lutein; (4) a hormone such as dehydroepiandrosterone, progesterone, pregnenolone, or melatonin; (5) an amino acid such as arginine, glutamine, lysine, phenylalanine, tyrosine, GABA, tryptophan, carnitine, or acetyl-l-carnitine; (6) a fatty acid such as a fish oil or flax seed oil; (7) a vita-nutrient such as coenzyme Q10; (8) a cartilage building nutrient such as glucosamine, chondroitin, or MSM, (9) a herb such as ginkgo biloba, echinacea, 5-HTP, St. John's wort, or saw palmetto; or (9) any combination thereof. The transdermal pharmaceutical composition may be topically administered to a human to prevent or reduce the likelihood of calcium deficiency or imbalances caused by calcium deficiency such as hypertension, high cholesterol, colon and rectal cancer, osteomalacia, rickets, osteoporosis, cardiovascular disease, preeclampsia, tooth decay, and premenstrual syndrome.

A dietary supplement of mitochondrial nutrients is designed for relieving stress, preventing and improving stress-related disorders, such as chronic fatigue syndrome, diabetes, age-associated cognitive dysfunction and diseases (Parkinson's and Alzheimer's disease). The supplement composition has the following nutrients: B vitamins (cyanocobalamin 2-1,000 ug, thiamin 1-1,000 mg, niacin 15-2,000 mg, pyridoxine 1-1,000 mg, Pantothenate 5-150 mg, folic acid 400-40,000 ug), alpha-tocopherol 10-800 mg, ascorbic acid 50-10,000 mg, calcium 20-2,000 mg, vitamin A 200-10,000 ug, alpha-lipoic acid 100-1,000 mg, N-acetyl cysteine 100-3,000 mg, L-carnosine 100-9,000 mg, tyrosine 100-9,000 mg, vanillin 10-100 mg, phosphatidylserine 10-800 mg, resveratrol 10-50 mg, dehydroepiandrosterone 1-50 mg, and melatonin 0.1-3 mg, all of which have been individually used experimentally or clinically for relieving stress, preventing and treating age- and stress-related disorders and diseases but no combination of these compounds has been used. Many embodiments also contain at least one adjunct ingredient such as coenzyme Q 10-200 mg, acetyl-L-carnitine 100-2,000 mg, choline 50-1,000 mg, and creatine 100-2,000 mg.

The present invention relates to an improved countermeasure for circadian and sleep disruption as caused by a traditional alarm clock. It incorporates a lighting system at the alarm clock that, prior to the preset waking time, will emit a light that gradually increases in intensity as it changes the ultraviolet spectrum of light it emits, so as to simulate the rising sun. This will ease the waking process for many people, especially those prone to simple disruptions of their circadian regulation. It may also be set to operate in a reverse mode so as to simulate the setting sun thus helping stimulate melatonin production and easing one into sleep.

A stent is provided with a composition which includes melatonin and paclitaxel for use in treating smooth muscle cell proliferation, such as stenosis and preventing restenosis in vascular vessels.

A detecting unit detects a sleep state of a user. If the user is awakened halfway through his / her sleep, a control unit controls a lighting device to irradiate a light in a waveband with relatively small melatonin-production suppression effect.

A combination hormone and melatonin therapy is provided to reduce the risk of developing, or to reduce the severity of, breast cancer by administering at least one estrogen hormone and optionally at least one progesterone-receptor-binding compound or composition and melatonin together, preferably at normal bed time.

The present invention involves a light system for stimulating or regulating neuroendocrine, circadian, and photoneural systems in mammals based upon the discovery of peak sensitivity ranging from 425-505 nm; a light meter system for quantifying light which stimulates or regulates mammalian circadian, photoneural, and neuroendocrine systems. The present invention also relates to translucent and transparent materials, and lamps or other light sources with or without filters capable of stimulating or regulating neuroendocrine, circadian, and photoneural systems in mammals. Additionally, the present invention involves treatment of mammals with a wide variety of disorders or deficits, including light responsive disorders, eating disorders, menstrual cycle disorders, non-specific alerting and performance deficits, hormone-sensitive cancers, and cardiovascular disorders.

The present invention provides a pharmaceutical composition for sublingual or buccal administration of actives with low to poor aqueous solubility, e.g. the indole hormone melatonin, which contains a solution of the active in a pharmaceutically acceptable solvent adsorbed or absorbed onto particles of a pharmaceutically acceptable carrier and methods of preparing and using the pharmaceutical composition.

The present disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of melatonin or other melatoninergic agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

The invention discloses an application of melatonin in reducing cadmium accumulation in plants. The application includes the following steps: (1) mixing melatonin and additives to form aqueous solution; (2) spraying the aqueous solution on plant leaf surfaces under cadmium stress or filling the aqueous solution in nutrient solution or soil where plants grow. The melatonin can quickly and efficiently reduce cadmium content in plant leaves, change distribution of cadmium ions in plant cells, and relieve damage of cadmium to cells; in addition, the melatonin is simple to prepare and convenient to use, does not cause product and environment pollution, does not generate phytotoxicity easily and has a wide application prospect.

The invention discloses novel application of melatonin to promotion of plant growth. A product with the melatonin as an active ingredient specifically can be a water solution of melatonin or an agriculturally acceptable carrier or solvent processed to be in an existing known form through a known method. The concentration of the water solution of melatonin specifically can be 10-100 micro mol / L, preferably 50 micro mol / L. A plant specifically can be a plant seedling, preferably a rape seedling. A method for promoting the plant growth specifically can comprise the following steps: irrigating soil for plant growth with the product with the melatonin as the active ingredient. The melatonin is endogenous metabolite, can be biodegraded while increasing the yield, is nontoxic, safe and free of residue to a human body, and can be used for production of lands for growing field crops and facility agriculture.

A novel biphasic pharmaceutial or nutraceutical composition delivers both an immediate and a sustained dose of a pharmaceutical or nutraceutical agent in the same unit dose. An oral unit dose of melatonin includes melatonin in a sustained-release matrix contained in a solid phase, such as a tablet of capsule, and also includes melatonin in a film dispersed on the surface of the solid phase. Approximately 80 to 90 weight percent of the total amount of melatonin of each unit is contained in the sustained-release matrix and the remainder in the film. The novel composition permits a mammal, including a human being, to both rapidly fall asleep and remain asleep for a desired period of time by releasing an immediate-release dose and a sustained-release dose of melatonin.

Supplemental compositions, and methods for administering same to a user, are provided for promoting a restful night's sleep by speedily inducing a person to fall asleep and to maintain sleep, as well as alleviating minor aches and pains so as to further improve the quality of a person sleep. The supplemental composition may include at least an extract of Valerian Root, an extract of Willow Bark and Melatonin or a derivative thereof. The supplemental composition may be provided for consumption at least one time daily, e.g., prior to sleep.

The invention relates to the field of medical preparations, in particular to an enteric solid preparation containing lycopene, resveratrol or melatonin and a preparation method of the enteric solid preparation. The enteric solid preparation comprises one or more of lycopene, resveratrol and melatonin as an active ingredient, water-soluble and / or enteric carrier adjuvants or other pharmaceutic adjuvants. The water-soluble carrier adjuvants can be used as water-soluble solid dispersoid carriers; and the enteric carrier adjuvants are enteric polymers and can be used as enteric solid dispersoid carriers or enteric coating film materials. The lycopene, the resveratrol and the melatonin of the enteric solid preparation have favorable dissolubility in the intestinal tract, so that the medicament, namely, the enteric solid preparation, can be rapidly dissolved and released in the intestinal tract, and thus absorption and bioavailability of the lycopene, the resveratrol and the melatonin are increased. The enteric solid preparation containing the lycopene, the resveratrol and the melatonin can be suitable for application and industrial production of oral preparations, such as tablets, particles, pellets, capsules, enteric capsules, enteric coating tablets, enteric coating pellets, enteric coating particles and the like.

The invention relates to melatonin solution capable of improving the anti-stress capability of a plant. The melatonin solution contains a solvent, wherein the concentration of melatonin in the solvent is 75-100mmol / L; the anti-stress capability is salt-resistant, cold-resistant and iron deficiency-resistant capability; the working concentration of the melatonin solution is 75-100micromol / L after the melatonin solution is diluted by distilled water; preparation steps are as follows: adding melatonin in the solvent suitable for being used in agricultural production, stirring and dissolving to obtain a finished melatonin solution product. According to the melatonin solution disclosed by the invention, simple and practicable effects are achieved, the operation is simple, the stability is good, and salt-resistant, cold-resistant and iron deficiency-resistant capability of the plant can be improved.

The invention is a melatonin double-layer controlled release tablet and making technique, using melatonin as main raw material, and composed of quick-release layer and sustained-release layer. The quick-release layerí»s components: melatonin 1-5%, Vitamin B6 3-15%, lactose 10-70%, pre-gel amylum 10-70%, hypromellose 0.03-0.3%, magnesium stearate 0.3-2% and SiO2 1.0-3.0%; the sustained layerí»s components: melatonin 2-6%, hypromellose 15-60%, stearic acid 15-65%, polyethylene glycol 10000 10-30%, and magnesium stearate 1.0-5.0%. It has efficacies of quickly hypnotizing and prolonging effective time of sleeping.

The present invention relates to methods for preventing the development of cancer or neurodegenerative diseases by administering N-Acetylcysteine (NAC), melatonin, or a combination thereof. The present invention also relates to methods for diagnosing cancer and / or neurdegenerative disease by detecting or determining the amount of dopamine metabolites, 4-CE, 2-CE, methylation of CE or CE-Q conjugates.

Disclosed herein are substituted naphthalene-based melatonin (MT) receptor modulators and / or 5-HT receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

A controlled release nutritional food supplement tablet having inner and an outer parts, the inner part being a slow release nucleus of melatonin and hydroxypropylmethylcellulose with the outer part being an immediate release cortex or coating of melatonin.

A multi-layered solid dosage form for oral administration for a multi-phasic controlled release of Melatonin is described. The solid dosage form is useful as a composition to promote and maintain a state of sleep in an individual.

A stent provided with a composition comprising melatonin and paclitaxel is described. The described stent is useful in treating smooth muscle cell proliferation, such as stenosis and preventing restenosis in vascular vessels.

This disclosure relates to the application of a photoluminescent material with a plurality of nanocrystals, such as quantum dots or Cornell dots, each capable of absorbing electromagnetic energy at a first wavelength and emitting the absorbed energy as a desired wavelength in the direction of a human retina. Preferably, the emitted wavelength is chosen for its ability to suppress naturally occurring melatonin, i.e., blue light. The disclosure also contemplates the placement of the photoluminescent material over the entire surface of a lens or on a portion of the lens to optimize the exposure to the desired wavelength while reducing the overall luminescence. Finally, the photoluminescent material can be applied as a coating, as part of a material applied to the lens, either superficially or in / within the lens, as part of eyewear, or even as an optical treatment system.

The invention provides a culture liquid for promoting ectogenesis of embryo vitrified by an open pulled straw (OPS) method after thawing. Frozen 2-cell embryo after thawing is cultured in the culture liquid containing 10<-9> mol / L of melatonin (MT), so that the blastula development rate of the embryo is improved and the number of the cells in the embryo is increased, thereby improving the embryo quality, and providing a beneficial reference for further developing the study of OPS cryopreservation of livestock embryos.

A method for treating or preventing symptoms of tardive dyskensia comprises administering melatonin to patient exhibiting or liable to develop such symptoms. The melatonin is administered in an amount effective to ameliorate or prevent symptoms of tardive dyskensia developing in the patient.

An illumination system (1) includes a lighting device (3); a manipulation device (6) for a user to manipulate when the user intends to fall asleep; a control unit (2) for detecting a start time of measuring a sleep latency based on a manipulation time at which the manipulation device is manipulated, the sleep latency being a time period from a time at which the user intends to fall asleep to a time at which the user falls asleep; and a memory unit (14) for storing a reference time obtained based on the start time of measuring the sleep latency detected by the control unit. The control unit includes a lighting device control (15) subunit performing an illumination control to reduce the user's melatonin suppression from a preset timing before the reference time stored in the memory.

The invention discloses an external preparation for treating vitligo and a preparation and using method thereof. The external preparation comprises the following components in portion by weight: 10 to 30 portions of radix salviae miltiorrhizae, 10 to 30 portions of rhizoma drynariae, 10 to 30 portions of herba ecliptae, 10 to 30 portions of angelica, 10 to 30 portions of dodder, 10 to 30 portions of white fructus tribuli, 10 to 30 portions of purslane, 10 to 30 portions of dark plum, 10 to 30 portions of cnidium fruit, 10 to 30 portions of prepared fleece-flower root, 10 to 30 portions of safflower, 10 to 30 portions of black sesame, 10 to 30 portions of szechuan lovage rhizome, 10 to 30 portions of gromwell root, 10 to 30 portions of honeysuckle, 10 to 30 portions of malaytea scurfpea fruit, 2 to 8 portions of radix euphorbiae ebractealatae, 10 to 15 portions of toad shell and 2 to 8 portions of chilopod. The external preparation can invigorate blood circulation and eliminate freckles, inhibit epidermis sulphydryl and melatonin, and activate the activity of tyrosinase so as to recover or accelerate the generation and the transfer of melanin and recover the color element of pathological skin; and the preparation method is simple, and can obtain good economic benefit.